Prevention of Posttransplant Cytomegalovirus Disease and Related Outcomes with Valganciclovir: A Systematic Review
Open Access
- 16 September 2008
- journal article
- review article
- Published by Elsevier in American Journal of Transplantation
- Vol. 8 (10) , 2111-2118
- https://doi.org/10.1111/j.1600-6143.2008.02369.x
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Valganciclovir as Treatment for Cytomegalovirus Disease in Solid Organ Transplant RecipientsClinical Infectious Diseases, 2008
- Valacyclovir Prophylaxis Versus Preemptive Valganciclovir Therapy to Prevent Cytomegalovirus Disease After Renal TransplantationAmerican Journal of Transplantation, 2008
- A Survey of CMV Prevention Strategies After Liver TransplantationAmerican Journal of Transplantation, 2007
- Leukopenia Complicates Cytomegalovirus Prevention After Renal Transplantation With Alemtuzumab InductionTransplantation, 2007
- Valganciclovir Preemptive Therapy for the Prevention of Cytomegalovirus Disease in High-Risk Seropositive Solid-Organ Transplant RecipientsTransplantation, 2006
- Pre-emptive Treatment for Cytomegalovirus Viremia to Prevent Cytomegalovirus Disease in Solid Organ Transplant RecipientsTransplantation, 2006
- Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas–kidney, and pancreas transplantationClinical Transplantation, 2004
- VALGANCICLOVIR FOR THE PROPHYLAXIS OF CYTOMEGALOVIRUS DISEASE IN PEDIATRIC LIVER TRANSPLANT RECIPIENTSTransplantation, 2004
- CYTOMEGALOVIRUS ANTIGENEMIA DIRECTED PRE-EMPTIVE PROPHYLAXIS WITH ORAL VERSUS I.V. GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN LIVER TRANSPLANT RECIPIENTS1Transplantation, 2000
- A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal AllograftsNew England Journal of Medicine, 1989